Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Ipsen initiated with a Hold at Berenberg » 05:15
11/24/21
11/24
05:15
11/24/21
05:15
IPSEY

Ipsen

$25.37 /

+ (+0.00%)

Berenberg analyst Diana…

Berenberg analyst Diana Na initiated coverage of Ipsen with a Hold rating and EUR 93 price target. The analyst thinks pharma sector fundamentals are "healthy and sustainable." For the European mid-cap pharma sector, she forecasts 6% annual sales growth and 8% earnings growth over the next five years.

ShowHide Related Items >><<
IPSEY Ipsen
$25.37 /

+ (+0.00%)

IPSEY Ipsen
$25.37 /

+ (+0.00%)

11/05/21 Morgan Stanley
Ipsen downgraded to Underweight from Equal Weight at Morgan Stanley
10/22/21 Credit Suisse
Ipsen price target raised to EUR 92 from EUR 90 at Credit Suisse
10/19/21 Barclays
Ipsen downgraded to Underweight from Overweight at Barclays
10/19/21 Exane BNP Paribas
Ipsen initiated with a Neutral at Exane BNP Paribas
Over a week ago
Conference/Events
Reuters Events to hold a virtual conference » 10:22
11/08/21
11/08
10:22
11/08/21
10:22
NVS

Novartis

$83.46 /

-0.165 (-0.20%)

, RHHBY

Roche

$50.20 /

-0.82 (-1.61%)

, TAK

Takeda Pharmaceutical

$14.33 /

+0.075 (+0.53%)

, ABT

Abbott

$125.27 /

+0.93 (+0.75%)

, MRK

Merck

$81.48 /

-0.13 (-0.16%)

, OTSKY

Otsuka

$20.11 /

-0.03 (-0.15%)

, SNY

Sanofi

$51.18 /

-0.11 (-0.21%)

, GSK

GlaxoSmithKline

$42.98 /

-0.5101 (-1.17%)

, IPSEY

Ipsen

$26.60 /

+ (+0.00%)

, ALKS

Alkermes

$30.01 /

-0.325 (-1.07%)

, AKBA

Akebia

$2.90 /

-0.03 (-1.03%)

, BMY

Bristol-Myers

$59.76 /

+0.31 (+0.52%)

, NVO

Novo Nordisk

$114.94 /

+1.535 (+1.35%)

, LLY

Eli Lilly

$263.00 /

-2.05 (-0.77%)

Pharma Marketing USA to…

Pharma Marketing USA to be held on November 8-10.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$14.33 /

+0.075 (+0.53%)

SNY Sanofi
$51.18 /

-0.11 (-0.21%)

RHHBY Roche
$50.20 /

-0.82 (-1.61%)

OTSKY Otsuka
$20.11 /

-0.03 (-0.15%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

NVO Novo Nordisk
$114.94 /

+1.535 (+1.35%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

IPSEY Ipsen
$26.60 /

+ (+0.00%)

GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

ALKS Alkermes
$30.01 /

-0.325 (-1.07%)

AKBA Akebia
$2.90 /

-0.03 (-1.03%)

ABT Abbott
$125.27 /

+0.93 (+0.75%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

11/05/21 UBS
Novartis downgraded to Neutral on lower near-term growth at UBS
11/05/21 UBS
Novartis downgraded to Neutral from Buy at UBS
10/27/21 JPMorgan
Novartis price target lowered to CHF 80 from CHF 84 at JPMorgan
10/12/21 Berenberg
Novartis price target lowered to CHF 88 from CHF 96 at Berenberg
RHHBY Roche
$50.20 /

-0.82 (-1.61%)

10/21/21 Benchmark
Biogen, Roche calls 'not helpful for Ionis story,' says Benchmark
10/19/21 William Blair
William Blair says Atea MOONSONG results raise concerns, but plunge 'premature'
10/13/21 Morgan Stanley
Roche price target raised to CHF 380 from CHF 370 at Morgan Stanley
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
TAK Takeda Pharmaceutical
$14.33 /

+0.075 (+0.53%)

10/29/21 Jefferies
Takeda Pharmaceutical upgraded to Buy from Hold at Jefferies
10/12/21 Piper Sandler
Poseida Therapeutics price target raised to $19 from $17 at Piper Sandler
10/06/21 Morgan Stanley
Morgan Stanley cuts Takeda to Equal Weight after Phase 2 study halted
10/06/21 Morgan Stanley
Takeda downgraded to Equal Weight from Overweight at Morgan Stanley
ABT Abbott
$125.27 /

+0.93 (+0.75%)

10/27/21
Fly Intel: Top five analyst upgrades
10/27/21 Atlantic Equities
Abbott upgraded to Overweight at Atlantic Equities on strong execution
10/27/21 Atlantic Equities
Abbott upgraded to Overweight from Neutral at Atlantic Equities
10/21/21 Morgan Stanley
Abbott price target raised to $146 from $136 at Morgan Stanley
MRK Merck
$81.48 /

-0.13 (-0.16%)

11/05/21 Cowen
Pfizer 'looks to have edge' in COVID oral antivirals, says Cowen
11/05/21 Benchmark
Regeneron downgraded to Hold from Buy at Benchmark
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
11/01/21 Argus
Merck upgraded to Buy from Hold at Argus
OTSKY Otsuka
$20.11 /

-0.03 (-0.15%)

07/14/21 Goldman Sachs
Otsuka downgraded to Sell from Neutral at Goldman Sachs
06/17/21 Daiwa
Otsuka upgraded to Outperform from Neutral at Daiwa
03/15/21 Daiwa
Otsuka downgraded to Neutral from Outperform at Daiwa
SNY Sanofi
$51.18 /

-0.11 (-0.21%)

11/01/21 HSBC
Sanofi upgraded to Buy from Hold at HSBC
10/25/21 H.C. Wainwright
Regeneron trial data reinforce bullish outlook on Dupixent, says H.C. Wainwright
10/14/21 JPMorgan
Sanofi price target raised to EUR 105 from EUR 100 at JPMorgan
09/27/21 SVB Leerink
Sanofi upgraded to Outperform at SVB Leerink following pullback
GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

11/05/21 Barclays
GlaxoSmithKline upgraded to Equal Weight from Underweight at Barclays
11/03/21 Morgan Stanley
GlaxoSmithKline price target raised to 1,580 GBp at Morgan Stanley
11/01/21 JPMorgan
GlaxoSmithKline price target raised to 1,580 GBp from 1,500 GBp at JPMorgan
10/28/21 Barclays
GlaxoSmithKline price target raised to 1,400 GBp from 1,350 GBp at Barclays
IPSEY Ipsen
$26.60 /

+ (+0.00%)

11/05/21 Morgan Stanley
Ipsen downgraded to Underweight from Equal Weight at Morgan Stanley
10/22/21 Credit Suisse
Ipsen price target raised to EUR 92 from EUR 90 at Credit Suisse
10/19/21 Barclays
Ipsen downgraded to Underweight from Overweight at Barclays
10/19/21 Exane BNP Paribas
Ipsen initiated with a Neutral at Exane BNP Paribas
ALKS Alkermes
$30.01 /

-0.325 (-1.07%)

10/28/21 Mizuho
Alkermes shares have 25% upside after selloff, says Mizuho
10/28/21 H.C. Wainwright
Alkermes price target raised to $30 from $25 at H.C. Wainwright
10/27/21 Stifel
Alkermes price target raised to $29 from $25 at Stifel
10/06/21 Jefferies
Alkermes upgraded to Buy from Hold at Jefferies
AKBA Akebia
$2.90 /

-0.03 (-1.03%)

07/15/21 Piper Sandler
Akebia approval path intact after FibroGen panel vote, says Piper Sandler
07/14/21 Morgan Stanley
FibroGen AdCom docs have likely read through for Akebia, says Morgan Stanley
06/01/21 H.C. Wainwright
Akebia NDA accepted with no FDA panel planned, says H.C. Wainwright
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

11/08/21 Wedbush
Wedbush bullish on 2seventy Bio, initiates with an Outperform
11/01/21 Argus
Bristol-Myers cut to Hold at Argus on generic competition threat to Revlimid
11/01/21 Argus
Bristol-Myers downgraded to Hold from Buy at Argus
10/26/21 RBC Capital
Aurinia Pharmaceuticals price target raised to $34 from $23 at RBC Capital
NVO Novo Nordisk
$114.94 /

+1.535 (+1.35%)

11/05/21 Deutsche Bank
Novo Nordisk price target raised to DKK 775 from DKK 735 at Deutsche Bank
11/04/21 Barclays
Novo Nordisk price target raised to DKK 750 from DKK 675 at Barclays
11/04/21 Credit Suisse
Novo Nordisk price target raised to DKK 670 from DKK 625 at Credit Suisse
11/04/21 JPMorgan
Novo Nordisk price target raised to DKK 800 from DKK 700 at JPMorgan
LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

10/27/21 Mizuho
Eli Lilly price target lowered to $272 from $279 at Mizuho
10/11/21
Fly Intel: Top five analyst upgrades
10/11/21 Berenberg
Eli Lilly upgraded to Buy from Hold at Berenberg
09/30/21 RBC Capital
Prothena price target raised to $82 from $59 at RBC Capital
SNY Sanofi
$51.18 /

-0.11 (-0.21%)

RHHBY Roche
$50.20 /

-0.82 (-1.61%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

NVO Novo Nordisk
$114.94 /

+1.535 (+1.35%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

ALKS Alkermes
$30.01 /

-0.325 (-1.07%)

AKBA Akebia
$2.90 /

-0.03 (-1.03%)

ABT Abbott
$125.27 /

+0.93 (+0.75%)

TAK Takeda Pharmaceutical
$14.33 /

+0.075 (+0.53%)

SNY Sanofi
$51.18 /

-0.11 (-0.21%)

RHHBY Roche
$50.20 /

-0.82 (-1.61%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

ABT Abbott
$125.27 /

+0.93 (+0.75%)

TAK Takeda Pharmaceutical
$14.33 /

+0.075 (+0.53%)

SNY Sanofi
$51.18 /

-0.11 (-0.21%)

RHHBY Roche
$50.20 /

-0.82 (-1.61%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

NVO Novo Nordisk
$114.94 /

+1.535 (+1.35%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

ALKS Alkermes
$30.01 /

-0.325 (-1.07%)

ABT Abbott
$125.27 /

+0.93 (+0.75%)

TAK Takeda Pharmaceutical
$14.33 /

+0.075 (+0.53%)

NVS Novartis
$83.46 /

-0.165 (-0.20%)

MRK Merck
$81.48 /

-0.13 (-0.16%)

LLY Eli Lilly
$263.00 /

-2.05 (-0.77%)

GSK GlaxoSmithKline
$42.98 /

-0.5101 (-1.17%)

BMY Bristol-Myers
$59.76 /

+0.31 (+0.52%)

ABT Abbott
$125.27 /

+0.93 (+0.75%)

Downgrade
Ipsen downgraded to Underweight from Equal Weight at Morgan Stanley » 07:04
11/05/21
11/05
07:04
11/05/21
07:04
IPSEY

Ipsen

$26.60 /

+ (+0.00%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin downgraded Ipsen to Underweight from Equal Weight with a price target of EUR 80, down from EUR 90. While the valuation "remains attractive," there is no catalyst Boutherin sees to drive a rerating ahead of a "risky" regulatory update for key pipeline asset palovarotene in the second half of 2022, the analyst tells investors.

ShowHide Related Items >><<
IPSEY Ipsen
$26.60 /

+ (+0.00%)

IPSEY Ipsen
$26.60 /

+ (+0.00%)

10/22/21 Credit Suisse
Ipsen price target raised to EUR 92 from EUR 90 at Credit Suisse
10/19/21 Barclays
Ipsen downgraded to Underweight from Overweight at Barclays
10/19/21 Exane BNP Paribas
Ipsen initiated with a Neutral at Exane BNP Paribas
10/11/21 JPMorgan
Ipsen price target raised to EUR 100 from EUR 95 at JPMorgan
Over a month ago
Recommendations
Ipsen price target raised to EUR 92 from EUR 90 at Credit Suisse » 14:13
10/22/21
10/22
14:13
10/22/21
14:13
IPSEY

Ipsen

$25.24 /

+0.07 (+0.28%)

Credit Suisse analyst…

Credit Suisse analyst Matthew Weston raised the firm's price target on Ipsen to EUR 92 from EUR 90 and keeps a Neutral rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$25.24 /

+0.07 (+0.28%)

IPSEY Ipsen
$25.24 /

+0.07 (+0.28%)

10/19/21 Barclays
Ipsen downgraded to Underweight from Overweight at Barclays
10/19/21 Exane BNP Paribas
Ipsen initiated with a Neutral at Exane BNP Paribas
10/11/21 JPMorgan
Ipsen price target raised to EUR 100 from EUR 95 at JPMorgan
10/07/21 Morgan Stanley
Ipsen price target raised to EUR 90 from EUR 88 at Morgan Stanley
Downgrade
Ipsen downgraded to Underweight from Overweight at Barclays » 05:59
10/19/21
10/19
05:59
10/19/21
05:59
IPSEY

Ipsen

$25.06 /

+ (+0.00%)

Barclays analyst Emily…

Barclays analyst Emily Field double downgraded Ipsen to Underweight from Overweight with a price target of EUR 75, down from EUR 92, into the Q3 earnings season.

ShowHide Related Items >><<
IPSEY Ipsen
$25.06 /

+ (+0.00%)

IPSEY Ipsen
$25.06 /

+ (+0.00%)

10/19/21 Exane BNP Paribas
Ipsen initiated with a Neutral at Exane BNP Paribas
10/11/21 JPMorgan
Ipsen price target raised to EUR 100 from EUR 95 at JPMorgan
10/07/21 Morgan Stanley
Ipsen price target raised to EUR 90 from EUR 88 at Morgan Stanley
08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
Initiation
Ipsen initiated with a Neutral at Exane BNP Paribas » 05:12
10/19/21
10/19
05:12
10/19/21
05:12
IPSEY

Ipsen

$25.06 /

+ (+0.00%)

Exane BNP Paribas…

Exane BNP Paribas initiated coverage of Ipsen with a Neutral rating and EUR 90 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$25.06 /

+ (+0.00%)

IPSEY Ipsen
$25.06 /

+ (+0.00%)

10/11/21 JPMorgan
Ipsen price target raised to EUR 100 from EUR 95 at JPMorgan
10/07/21 Morgan Stanley
Ipsen price target raised to EUR 90 from EUR 88 at Morgan Stanley
08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
Recommendations
Ipsen price target raised to EUR 100 from EUR 95 at JPMorgan » 12:21
10/11/21
10/11
12:21
10/11/21
12:21
IPSEY

Ipsen

$24.76 /

+ (+0.00%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Ipsen to EUR 100 from EUR 95 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$24.76 /

+ (+0.00%)

IPSEY Ipsen
$24.76 /

+ (+0.00%)

10/07/21 Morgan Stanley
Ipsen price target raised to EUR 90 from EUR 88 at Morgan Stanley
08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
Recommendations
Ipsen price target raised to EUR 90 from EUR 88 at Morgan Stanley » 12:59
10/07/21
10/07
12:59
10/07/21
12:59
IPSEY

Ipsen

$24.76 /

+1.33 (+5.68%)

Morgan Stanley analyst…

Morgan Stanley analyst Thibault Boutherin raised the firm's price target on Ipsen to EUR 90 from EUR 88 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$24.76 /

+1.33 (+5.68%)

IPSEY Ipsen
$24.76 /

+1.33 (+5.68%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
Conference/Events
Ipsen participates in a conference call with JPMorgan » 10:04
09/29/21
09/29
10:04
09/29/21
10:04
IPSEY

Ipsen

$23.64 /

+0.26 (+1.11%)

European Healthcare…

European Healthcare Analysts hold a conference call with CEO Loew on September 29 at 11 am hosted by JPMorgan.

ShowHide Related Items >><<
IPSEY Ipsen
$23.64 /

+0.26 (+1.11%)

IPSEY Ipsen
$23.64 /

+0.26 (+1.11%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
Conference/Events
European Society for Medical Oncology to hold a virtual meeting » 04:55
09/21/21
09/21
04:55
09/21/21
04:55
ABBV

AbbVie

$106.42 /

-1.35 (-1.25%)

, AYLA

Ayala Pharmaceuticals

$12.00 /

-0.31 (-2.52%)

, DCPH

Deciphera

$32.28 /

-0.8 (-2.42%)

, GMAB

Genmab

$42.88 /

-0.16 (-0.37%)

, LPTX

Leap Therapeutics

$2.78 /

+0.125 (+4.72%)

, ORIC

Oric Pharmaceuticals

$24.54 /

-0.67 (-2.66%)

, SYNH

Syneos Health

$93.51 /

-0.83 (-0.88%)

, BGNE

BeiGene

$398.49 /

-5.03 (-1.25%)

, BMY

Bristol-Myers

$60.50 /

-0.82 (-1.34%)

, BYSI

BeyondSpring

$15.37 /

-7.63 (-33.17%)

, CALA

Calithera Biosciences

$2.18 /

-0.07 (-3.11%)

, GILD

Gilead

$70.97 /

-0.64 (-0.89%)

, GH

Guardant Health

$129.18 /

-2.57 (-1.95%)

, LLY

Eli Lilly

$231.74 /

+1.57 (+0.68%)

, IPSEY

Ipsen

$24.03 /

+0.105 (+0.44%)

, EXAS

Exact Sciences

$105.28 /

-2.97 (-2.74%)

, IDYA

Ideaya Biosciences

$26.22 /

-0.68 (-2.53%)

, GSK

GlaxoSmithKline

$38.84 /

-0.1 (-0.26%)

, RHHBY

Roche

$45.57 /

-0.5 (-1.09%)

, REGN

Regeneron

$641.33 /

-10.43 (-1.60%)

, PFE

Pfizer

$44.22 /

+0.325 (+0.74%)

, TAK

Takeda Pharmaceutical

$17.07 /

-0.095 (-0.55%)

, TMO

Thermo Fisher

$589.96 /

-6.64 (-1.11%)

, TCRR

TCR2 Therapeutics

$9.39 /

-0.61 (-6.10%)

, VERU

Veru

$8.45 /

-0.48 (-5.38%)

, VBLT

VBL Therapeutics

$2.23 /

-0.085 (-3.67%)

, VTRS

Viatris

$13.33 /

-0.24 (-1.77%)

, NVS

Novartis

$82.81 /

-0.68 (-0.81%)

ESMO 2021 Virtual…

ESMO 2021 Virtual Congress will be held on September 16-21. Webcast Link

ShowHide Related Items >><<
VTRS Viatris
$13.33 /

-0.24 (-1.77%)

VERU Veru
$8.45 /

-0.48 (-5.38%)

VBLT VBL Therapeutics
$2.23 /

-0.085 (-3.67%)

TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

TCRR TCR2 Therapeutics
$9.39 /

-0.61 (-6.10%)

TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

SYNH Syneos Health
$93.51 /

-0.83 (-0.88%)

RHHBY Roche
$45.57 /

-0.5 (-1.09%)

REGN Regeneron
$641.33 /

-10.43 (-1.60%)

PFE Pfizer
$44.22 /

+0.325 (+0.74%)

ORIC Oric Pharmaceuticals
$24.54 /

-0.67 (-2.66%)

NVS Novartis
$82.81 /

-0.68 (-0.81%)

LPTX Leap Therapeutics
$2.78 /

+0.125 (+4.72%)

LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

IPSEY Ipsen
$24.03 /

+0.105 (+0.44%)

IDYA Ideaya Biosciences
$26.22 /

-0.68 (-2.53%)

GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

GILD Gilead
$70.97 /

-0.64 (-0.89%)

GH Guardant Health
$129.18 /

-2.57 (-1.95%)

EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

DCPH Deciphera
$32.28 /

-0.8 (-2.42%)

CALA Calithera Biosciences
$2.18 /

-0.07 (-3.11%)

BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

AYLA Ayala Pharmaceuticals
$12.00 /

-0.31 (-2.52%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Barclays
Regenxbio price target raised to $82 from $79 at Barclays
09/13/21 Chardan
Regenxbio pact with AbbVie accelerates RGX-314 'value capture,' says Chardan
09/08/21 JPMorgan
AbbVie offers 'best risk/reward story in the group,' says JPMorgan
AYLA Ayala Pharmaceuticals
$12.00 /

-0.31 (-2.52%)

07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with Buy, $29 target at Ladenburg
07/13/21 Ladenburg
Ayala Pharmaceuticals initiated with a Buy at Ladenburg
12/07/20
Fly Intel: Top five analyst initiations
12/07/20 Roth Capital
Ayala Pharmaceuticals initiated with a Buy at Roth Capital
DCPH Deciphera
$32.28 /

-0.8 (-2.42%)

08/04/21 H.C. Wainwright
Deciphera price target lowered to $70 from $75 at H.C. Wainwright
05/05/21 Barclays
Deciphera price target lowered to $65 from $70 at Barclays
05/05/21 H.C. Wainwright
Deciphera price target lowered to $75 from $80 at H.C. Wainwright
05/05/21 Piper Sandler
Deciphera price target lowered to $60 from $75 at Piper Sandler
GMAB Genmab
$42.88 /

-0.16 (-0.37%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
LPTX Leap Therapeutics
$2.78 /

+0.125 (+4.72%)

09/19/21 Piper Sandler
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
ORIC Oric Pharmaceuticals
$24.54 /

-0.67 (-2.66%)

07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy after tumor data at Citi
07/06/21 Citi
Oric Pharmaceuticals upgraded to Buy from Neutral at Citi
03/25/21 H.C. Wainwright
Oric Pharmaceuticals price target raised to $54 from $52 at H.C. Wainwright
01/25/21 Citi
Oric Pharmaceuticals downgraded to Neutral from Buy at Citi
SYNH Syneos Health
$93.51 /

-0.83 (-0.88%)

08/04/21 Credit Suisse
Syneos Health assumed with an Outperform at Credit Suisse
07/13/21 Barclays
Syneos Health price target raised to $102 from $90 at Barclays
06/02/21 Truist
Syneos Health price target raised to $104 from $88 at Truist
04/30/21 Mizuho
Syneos Health price target raised to $90 from $82 at Mizuho
BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

06/14/21 SVB Leerink
BeiGene price target raised to $417 from $388 at SVB Leerink
03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

09/20/21 H.C. Wainwright
BeyondSpring price target lowered to $65 from $100 at H.C. Wainwright
09/08/21 Baird
BeyondSpring initiated with an Outperform at Baird
08/04/21 Evercore ISI
BeyondSpring price target raised to $95 from $30 at Evercore ISI
08/04/21 William Blair
BeyondSpring may have new standard of care in lung cancer, says William Blair
CALA Calithera Biosciences
$2.18 /

-0.07 (-3.11%)

01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform at SVB Leerink
01/05/21 SVB Leerink
Calithera Biosciences downgraded to Market Perform from Outperform at SVB Leerink
01/05/21 Citi
Calithera Biosciences price target lowered to $5 from $10 at Citi
01/05/21 H.C. Wainwright
Calithera Biosciences price target lowered to $4 from $9.50 at H.C. Wainwright
GILD Gilead
$70.97 /

-0.64 (-0.89%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GH Guardant Health
$129.18 /

-2.57 (-1.95%)

08/09/21 Canaccord
Guardant Health price target lowered to $180 from $195 at Canaccord
06/21/21 Wells Fargo
Guardant Health price target raised to $160 from $145 at Wells Fargo
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Raymond James
Guardant Health initiated with a Market Perform at Raymond James
LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

09/02/21 SVB Leerink
AbbVie price target lowered to $142 from $148 at SVB Leerink
08/30/21 Cowen
Eli Lilly price target raised to $300 from $250 at Cowen
08/30/21 Citi
Lexicon price target raised to $20 from $13 at Citi
IPSEY Ipsen
$24.03 /

+0.105 (+0.44%)

08/16/21 Morgan Stanley
Ipsen price target lowered to EUR 88 from EUR 92 at Morgan Stanley
08/03/21 Morgan Stanley
Ipsen price target raised to EUR 92 from EUR 85 at Morgan Stanley
08/02/21 Societe Generale
Ipsen price target raised to EUR 101 from EUR 90 at Societe Generale
07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/15/21 Canaccord
Exact Sciences progress in MRD space a positive, says Canaccord
09/01/21 Baird
UnitedHealth update to CRC screening coverage not a surprise, says Baird
IDYA Ideaya Biosciences
$26.22 /

-0.68 (-2.53%)

06/03/21 Baird
Ideaya Biosciences assumed with an Outperform at Baird
04/22/21 Roth Capital
Ideaya Biosciences price target raised to $38 from $31 at Roth Capital
04/19/21 H.C. Wainwright
Ideaya Biosciences price target raised to $35 from $29 at H.C. Wainwright
04/16/21 Roth Capital
Ideaya Biosciences price target raised to $31 from $23 at Roth Capital
GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

09/20/21 UBS
GlaxoSmithKline price target lowered to 1,460 GBp from 1,540 GBp at UBS
08/26/21 UBS
GlaxoSmithKline price target raised to 1,540 GBp from 1,485 GBp at UBS
08/20/21 JPMorgan
GlaxoSmithKline price target raised to 1,500 GBp from 1,300 GBp at JPMorgan
RHHBY Roche
$45.57 /

-0.5 (-1.09%)

09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
REGN Regeneron
$641.33 /

-10.43 (-1.60%)

09/15/21 Cantor Fitzgerald
Regeneron price target raised to $700 from $670 at Cantor Fitzgerald
09/15/21 H.C. Wainwright
Regeneron price target raised to $831 from $787 at H.C. Wainwright
09/15/21 Piper Sandler
Regeneron price target raised to $690 from $675 at Piper Sandler
09/09/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$44.22 /

+0.325 (+0.74%)

09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
08/03/21 Piper Sandler
Arcturus strength attributable to large pharma's interest in mRNA, says Piper
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

09/20/21 SVB Leerink
Thermo Fisher price target raised to $675 from $600 at SVB Leerink
09/20/21 JPMorgan
Thermo Fisher price target raised to $700 from $600 at JPMorgan
09/20/21 KeyBanc
Thermo Fisher price target raised to $710 from $555 at KeyBanc
09/20/21 Citi
Thermo Fisher price target raised to $620 from $535 at Citi
TCRR TCR2 Therapeutics
$9.39 /

-0.61 (-6.10%)

09/20/21 Truist
TCR2 Therapeutics price target lowered to $29 from $40 at Truist
09/20/21 H.C. Wainwright
TCR2 Therapeutics price target lowered to $25 from $37 at H.C. Wainwright
09/17/21 Wedbush
TCR2 Therapeutics downgraded to Neutral from Outperform at Wedbush
08/06/21 BMO Capital
TCR2 Therapeutics price target lowered to $44 from $53 at BMO Capital
VERU Veru
$8.45 /

-0.48 (-5.38%)

04/13/21 Jefferies
Veru initiated with a Buy at Jefferies
02/11/21 Oppenheimer
Veru price target raised to $24 from $19 at Oppenheimer
02/11/21 H.C. Wainwright
Veru price target raised to $22 from $17 at H.C. Wainwright
02/09/21 H.C. Wainwright
Veru price target raised to $17 from $12 at H.C. Wainwright
VBLT VBL Therapeutics
$2.23 /

-0.085 (-3.67%)

08/30/21 Roth Capital
Roth bullish on VBL Therapeutics as U.S. Phase 3 OVAL trial enrollment resumes
06/15/21 Roth Capital
Roth does not see material change to VBL readout timelines
06/03/21 Roth Capital
Roth Capital ups VBL Therapeutics target to $7 on OVAL primary endpoint update
05/18/21 Guggenheim
VBL Therapeutics initiated with a Buy at Guggenheim
VTRS Viatris
$13.33 /

-0.24 (-1.77%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
NVS Novartis
$82.81 /

-0.68 (-0.81%)

09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
VTRS Viatris
$13.33 /

-0.24 (-1.77%)

VERU Veru
$8.45 /

-0.48 (-5.38%)

VBLT VBL Therapeutics
$2.23 /

-0.085 (-3.67%)

TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

TCRR TCR2 Therapeutics
$9.39 /

-0.61 (-6.10%)

TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

SYNH Syneos Health
$93.51 /

-0.83 (-0.88%)

RHHBY Roche
$45.57 /

-0.5 (-1.09%)

REGN Regeneron
$641.33 /

-10.43 (-1.60%)

PFE Pfizer
$44.22 /

+0.325 (+0.74%)

ORIC Oric Pharmaceuticals
$24.54 /

-0.67 (-2.66%)

NVS Novartis
$82.81 /

-0.68 (-0.81%)

LPTX Leap Therapeutics
$2.78 /

+0.125 (+4.72%)

LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

IDYA Ideaya Biosciences
$26.22 /

-0.68 (-2.53%)

GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

GILD Gilead
$70.97 /

-0.64 (-0.89%)

GH Guardant Health
$129.18 /

-2.57 (-1.95%)

EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

DCPH Deciphera
$32.28 /

-0.8 (-2.42%)

CALA Calithera Biosciences
$2.18 /

-0.07 (-3.11%)

BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

AYLA Ayala Pharmaceuticals
$12.00 /

-0.31 (-2.52%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

  • 08
    Jul
  • 03
    Jun
  • 04
    May
  • 09
    Apr
  • 01
    Mar
  • 18
    Feb
  • 20
    Jan
  • 02
    Dec
  • 02
    Dec
  • 19
    Nov
  • 13
    Nov
  • 07
    Oct
TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

SYNH Syneos Health
$93.51 /

-0.83 (-0.88%)

RHHBY Roche
$45.57 /

-0.5 (-1.09%)

REGN Regeneron
$641.33 /

-10.43 (-1.60%)

PFE Pfizer
$44.22 /

+0.325 (+0.74%)

NVS Novartis
$82.81 /

-0.68 (-0.81%)

LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

GILD Gilead
$70.97 /

-0.64 (-0.89%)

EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

VERU Veru
$8.45 /

-0.48 (-5.38%)

TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

RHHBY Roche
$45.57 /

-0.5 (-1.09%)

REGN Regeneron
$641.33 /

-10.43 (-1.60%)

PFE Pfizer
$44.22 /

+0.325 (+0.74%)

ORIC Oric Pharmaceuticals
$24.54 /

-0.67 (-2.66%)

NVS Novartis
$82.81 /

-0.68 (-0.81%)

LPTX Leap Therapeutics
$2.78 /

+0.125 (+4.72%)

LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

IDYA Ideaya Biosciences
$26.22 /

-0.68 (-2.53%)

GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

GILD Gilead
$70.97 /

-0.64 (-0.89%)

GH Guardant Health
$129.18 /

-2.57 (-1.95%)

EXAS Exact Sciences
$105.28 /

-2.97 (-2.74%)

BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

BGNE BeiGene
$398.49 /

-5.03 (-1.25%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

VTRS Viatris
$13.33 /

-0.24 (-1.77%)

VERU Veru
$8.45 /

-0.48 (-5.38%)

TMO Thermo Fisher
$589.96 /

-6.64 (-1.11%)

TAK Takeda Pharmaceutical
$17.07 /

-0.095 (-0.55%)

REGN Regeneron
$641.33 /

-10.43 (-1.60%)

PFE Pfizer
$44.22 /

+0.325 (+0.74%)

LLY Eli Lilly
$231.74 /

+1.57 (+0.68%)

GSK GlaxoSmithKline
$38.84 /

-0.1 (-0.26%)

GILD Gilead
$70.97 /

-0.64 (-0.89%)

BYSI BeyondSpring
$15.37 /

-7.63 (-33.17%)

BMY Bristol-Myers
$60.50 /

-0.82 (-1.34%)

ABBV AbbVie
$106.42 /

-1.35 (-1.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.